Comcapsy 700mg/30mg Tablet

Comcapsy 700mg/30mg Tablets contain 700 mg of Capecitabine and 30 mg of Cyclophosphamide and are used for the treatment of cancer.

Uses of Comcapsy 700mg/30mg Tablet

• Breast cancer
• Colorectal cancer
• Stomach cancer
• Ovarian cancer

How does Comcapsy 700mg/30mg Tablet work?

Capecitabine is converted to 5-FU, which inhibits thymidylate synthase, an enzyme necessary for DNA production, leading to the death of cancer cells. Cyclophosphamide alkylates DNA, causing cross-linking and inhibiting DNA replication, which leads to apoptosis of cancer cells.

How to Use & Dosage

The healthcare professional will decide the dose schedule depending on the type of cancer, the stage of the disease, and how the patient is responding. It is usually given in cycles with breaks in between.

Possible Side Effects

• Nausea
• Vomiting
• Diarrhea
• Hand-foot syndrome
• Fatigue
• Hair loss
• Bone marrow suppression
• Hemorrhagic cystitis

Safety Advice

⚠️ Liver

Both Capecitabine and Cyclophosphamide are metabolised and excreted by the liver, and regular monitoring of liver function is necessary. According to liver function, dose adjustment may be required. Discuss this with your doctor.

🩺 Kidney

Both Capecitabine and Cyclophosphamide are metabolized by and eliminated through the kidneys; therefore, regular monitoring of renal function is required. Dose adjustments may be needed based on kidney function. Please talk with your healthcare provider.

🤰 Pregnancy

There is clear evidence of risk to the human fetus from taking Comcapsy 700mg/30mg Tablets during pregnancy. Please talk to your healthcare provider.

🤱 Breastfeeding

Do not take Comcapsy 700mg/30mg Tablets while breastfeeding. There is evidence that the medicine may be unsafe for the nursing infant. Consult your doctor.

🍺 Alcohol

Limit or avoid alcohol during treatment. Please discuss this with your healthcare provider.

Storage Instructions

Store in a cool, dry place away from moisture and heat. Follow the specific storage instructions provided with the medication.

References

• FDA (Genentech). XELODA (capecitabine) Full Prescribing Information. 2024.
• Ahmad SS, Reinius MAV, et al. Cyclophosphamide: Basic Pharmacology and Clinical Applications. Br J Hosp Med. 2019;80(10):1-11.
• Ganesan P, Rajendranath R, et al. Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from the ENCLOSE phase 2/3 randomized multicenter study. Breast. 2021;60:265-272.
• Cortes J, Codacci-Pisanelli G, et al. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer. Ann Oncol. 2007;18(6):1017-1023.
• Goodman & Gilman’s. The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill.
• Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.

Disclaimer

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.